Shares of ZS Pharma (ZSPH) touched a fresh record high after resuming trade Thursday afternoon following a Bloomberg report noting Actelion Ltd. CEO Jean-Paul Clozel made a preliminary takeover offer in August, in a deal valuing the biopharmaceutical firm at $2.5 billion.
ZSPH was up almost 32% in recent afternoon trade, with a new 52-week range of $31.07 to $84.85. The company has a current market cap of $1.93 billion.
Sources close to the matter said it is unclear whether the two companies held talks and how ZS Pharma replied to the offer.
Switzerland-based Actelion is currently reviewing a number of possible acquisitions, another source told Bloomberg.
Price: 76.63 Price Change: +18.44 Percent Change: +31.69